NCT03303547 Concordance of Imaging and Pathology Diagnosis of Extranodal Tumour Deposits
| NCT ID | NCT03303547 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Imperial College London |
| Condition | Adenocarcinoma of the Rectum |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2017-10-16 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 200 participants in total. It began in 2017-10-16 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Any patient with a suspected primary adenocarcinoma of the colon, sigmoid or rectum undergoing surgery are eligible. The date of surgery must be known prior to registration. This trial aims to determine if image mapping techniques can improve the concordance between imaging and pathology detection of tumour deposits. Lymph nodes and tumour deposits will be identified on pre-operative scans and mapped by radiologists then shared with pathologists prior to processing the resected specimen. Patients will be managed at their local hospital with standard follow-up. Patients will be followed up for 5 years.
Eligibility Criteria
Inclusion Criteria: 1. Suspected primary adenocarcinoma of the colon, sigmoid or rectum (proven by biopsy taken as part of routine clinical practice, patients to be withdrawn if not subsequently adenocarcinoma on pathology). 2. Amenable to surgical resection. 3. Disease spread assessed on imaging 4. Patients having primary surgery and those undergoing neoadjuvant treatment will be included. 5. All must have had baseline staging scans and those undergoing neoadjuvant therapy must also have had a post-treatment scan. 6. Patients aged 16 years and over Exclusion Criteria: 1. Patients with recurrent tumours 2. Synchronous tumours 3. Under the age of 16 years 4. Unable to give informed consent.
Contact & Investigator
Gina Brown, MD
PRINCIPAL INVESTIGATOR
Imperial College London
Frequently Asked Questions
Who can join the NCT03303547 clinical trial?
This trial is open to participants of all sexes, aged 16 Years or older, studying Adenocarcinoma of the Rectum. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03303547 currently recruiting?
Yes, NCT03303547 is actively recruiting participants. Contact the research team at c.martin1@imperial.ac.uk for enrollment information.
Where is the NCT03303547 trial being conducted?
This trial is being conducted at London, United Kingdom.
Who is sponsoring the NCT03303547 clinical trial?
NCT03303547 is sponsored by Imperial College London. The principal investigator is Gina Brown, MD at Imperial College London. The trial plans to enroll 200 participants.